News-Medical.Net on MSN14h
Researchers receive $2.7 million NIH grant to develop the next generation of synthetic blood
Blood loss is the leading cause of death in trauma patients between the ages of 1 and 46 years, largely because they cannot ...
Exploring the link between inflammation and heart disease
A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...
AHA/ASA Journals8h
Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...
Zacks Investment Research on MSN4h
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first ...
Hemophilia News Today22h
Fitusiran, now Qfitlia, approved by FDA for hemophilia A, B patients
The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or ...